Compare Inovio Pharmaceuticals Inc (INO) vs The Magnum Ice Cream Company N.V. Ordinary Shares (MICC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs The Magnum Ice Cream Company N.V. Ordinary Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $0.96 (market cap $101.95M), while The Magnum Ice Cream Company N.V. Ordinary Shares trades at $18.6 (market cap $10.98B). The key difference: The Magnum Ice Cream Company N.V. Ordinary Shares is far larger — about 107.7× Inovio Pharmaceuticals Inc's market cap, and The Magnum Ice Cream Company N.V. Ordinary Shares is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and The Magnum Ice Cream Company N.V. Ordinary Shares for 0 Days on average.
| INO | MICC | |
|---|---|---|
Market Cap | $101.95M | $10.98B |
Volume | 2,985,847 | 789,308 |
Sector | Health | Consumer Staples |
52-Week High | $2.60 | $20.42 |
52-Week Low | $0.66 | $13.06 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $73.28M | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.
The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About The Magnum Ice Cream Company N.V. Ordinary Shares
The Magnum Ice Cream Company N.V. manufactures and sells ice cream and frozen desserts through brands including Magnum, Ben & Jerry's, Wall's, and Cornetto, distributing across roughly 80 countries.
Read more on MICC →
